Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06288997
Other study ID # TFYuan_tACS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 21, 2021
Est. completion date November 9, 2023

Study information

Verified date October 2023
Source Shanghai Mental Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A growing body of evidence suggests a wide range of brain areas are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial alternating current stimulation (tACS) over prefrontal cortex reduces craving for meth dependences. In this study, the investigators investigated whether a current level of 15mA with a patented frequency of 77.5Hz tACS intervention of prefrontal cortex cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.


Description:

The study will be conducted at the drug rehabilitation center in China. The whole procedure includes enrollment, pre-intervention evaluation, intervention (for 2 weeks, twice daily, 10 times a week, 20 times in total), post-intervention evaluation and one month follow up evaluation. In enrollment session, participants are recruited according to inclusion criteria. Sample size was calculated by GPower 3.1.9.4. As Hi-tACS has not been investigated in drug addiction, therefore, according to the previous study 'Transcranial alternating current stimulation for treating depression: a randomized controlled trial', the investigators choose the effect size as 1.2. After calculation, the sample size per group should be at least 20. A total of sample size should be 40. Considering the rate of drop-out during the treatment, the investigators set the sample size as 60 (30 per group). In the pre-intervention evaluation, firstly, participants need complete a questionnaire to assess their demographic information, drug addiction history and drug abstinence. And then are assigned to either active group or sham group according to the counterbalance of their basic demographic and drug use information. Then, participants need complete craving, cognitive ability and electroencephalogram (EEG) assessment. For craving assessing, participants are shown a video of methamphetamine usage for 5 minutes, and then rated on the visual analogue scale (0 means completely undesired and 100 means extremely wanting) to report their craving for methamphetamine. For cognitive ability and EEG signal assessing, the whole process is conducted on the computer according to instructions. In the intervention session, tACS stimulates the scalp with three Nexalin electrodes (Nexalin Technology, Inc., Houston, TX, USA): the locations of electrodes are determined according to international 10/20 system for EEG recording, and a 4.45 × 9.53cm electrode is placed above the forehead (Fpz, Fp1, and Fp2), the other two 3.18 × 3.81cm electrodes are placed above both mastoid areas. The active group received 77.5 Hz tACS for 40 minutes per session. The sham group received treatment with identical technical parameters, which induced scalp sensations but without penetration of the electric field into the brain. Post-intervention evaluation and one month follow up evaluation are the same as in pre-intervention evaluation. To ensure study quality, some measures are taken as bellow: Researchers and drug rehabilitation staff will work together in whole process and the data will be converted into electronic versions once finishing each evaluation. In the intervention, patients, operators, and raters were blind to treatment condition. Each patient is assigned a tACS device (real or sham) and raters are not present while treatments are administered. After each treatment times, any side effect from participant's report are recorded to assure the safety and feasibility. Statistical analyses will be performed using R Studio and Matlab. The principal statistical analysis will be performed using the linear mixed effect model. For details, piecewise linear mixed effect models will be conducted according to the changes patterns of scores (craving, BIS, BDI, BAI, PSQI) over time. The interaction term will be included in the linear mixed effect models to describe the changing rate (slope) difference between treatment groups. Pairwise comparison for craving/BIS/BAI/BDI/PSQI reduction speed before and after the treatment period, and the comparisons of follow-up after treatment to baseline across treatment groups, will be evaluated through the piecewise linear mixed effect models. Linear models will be employed, after confirming the normality of score changes. The Person's correlation and Spearman's correlation will be conducted to estimate the corraltion between symptoms and score changes. In addition, significant results identified will be checked for consistency and robustness. All missing data will be recorded and marked.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date November 9, 2023
Est. primary completion date May 9, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Methamphetamine dependents - middle school degree or above Exclusion Criteria: - Have contraindications to rTMS (head trauma, epilepsy or history of epilepsy, metal implant etc.) - psychiatric illnesses - intellectual impairment (IQ<90)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
transcranial alternating current stimulation
tACS with a current level of 15mA with a patented frequency of 77.5Hz.
sham tACS
tACS without stimulation

Locations

Country Name City State
China Beijing Tiantanghe Addiction Rehab Center Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other side effect measurements The side effect is measured by Side effect scale, including ten types of adverse effects, such as headache, pricking, sleeplessness etc. The score ranged from 0 to 100, higher score indicates severe adverse effect. every day after each intervention time for the 2 weeks intervention time period
Primary Changes of Cue-induced craving Subjective craving (cue induced, 0-100 based VAS, craving scale) the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary Changes of cognition: behavioral inhibition using cognitive task: stop-signal task the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary Changes of cognition: choice under ambiguity using cognitive task: choice under risk and ambiguity. The score of probability for risky choice is the major outcome, higher means more inclined to take risks. the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary changes of neural mechanism based on resting-state EEG, the five power oscillations will be calculated (Delta band, Theta band, Alpha band, Beta band, and Gamma band). the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary Changes of depression status the depression status is measured by Beck Depression inventory scale. The questionnaire is a 21-question multiple-choice self-report inventory, score ranged from 0 to 63, high score means worse depression. the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary Changes of anxiety status Anxiety status is measured by Beck anxiety inventory scale,it consists of 21 self-reported items (four-point scale) used to assess the intensity of physical and cognitive anxiety symptoms. Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63). higher score means worse anxiety. the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary Changes of sleep status sleep status measured by Pittsburgh Sleep Quality Index scale (PSQI). The global PSQI score is calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality. the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary Changes of impulsivity Impulsivity is measured by Barratt Impulsiveness Scale, the total scores can range from 30 to 120. Higher score means higher impulsivity. the day before intervention, 2 weeks after intervention, 3 months after intervention
Secondary event-related potential in passive viewing task Theamplitude of late positive potential (LPP) was considered as a major outcome of the drug-cue related ERP, higher LPP is related to higher craving. the day before intervention, 2 weeks after intervention, 3 months after intervention
See also
  Status Clinical Trial Phase
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT04449055 - Pilot TMS for Methamphetamine Use Disorder N/A
Active, not recruiting NCT05162391 - Inflammation in Methamphetamine and STIs (IMSTI) N/A
Completed NCT03336866 - Study of Antibody for Methamphetamine Outpatient Therapy Phase 1/Phase 2
Not yet recruiting NCT06233799 - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder Phase 3
Not yet recruiting NCT03748875 - The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents N/A
Recruiting NCT03341078 - Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users Phase 2
Active, not recruiting NCT03910608 - Paired Associative Stimulation in Methamphetamine Addiction N/A
Terminated NCT05283304 - Monthly Injectable BUP for MA Use Disorder (MURB) Trial Phase 2
Completed NCT04563962 - Contingency Management for PrEP Adherence and/or Methamphetamine Use N/A
Not yet recruiting NCT05334914 - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals N/A
Terminated NCT05034874 - Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 Phase 2
Recruiting NCT06434818 - Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders Phase 2
Recruiting NCT06027814 - MHealth Incentivized Adherence Plus Patient Navigation N/A
Completed NCT04544124 - Delivering Contingency Management in Outpatient Addiction Treatment N/A
Completed NCT01217970 - Safety Interaction Trial Ibudilast and Methamphetamine Phase 1
Completed NCT03825536 - Effect of Methamphetamine on Residual Latent HIV Disease Study Phase 4
Recruiting NCT03470480 - rTMS for Craving in Methamphetamine Use Disorder N/A
Recruiting NCT05128071 - PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT) Early Phase 1